Evaxion to Showcase at Multiple Conferences in Late 2025
Evaxion's Upcoming Conferences: Evaxion A/S will present scientific and company updates at various conferences in the US, Europe, and Asia from September to December 2025, including significant events like the ESMO Congress.
Engagement with Stakeholders: The company aims to engage with stakeholders and potential partners during these conferences to explore business partnerships and scientific collaborations.
Innovative Technology: Evaxion specializes in AI-Immunology™ powered vaccines, focusing on developing personalized cancer vaccines and immunotherapies for infectious diseases.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the company's future performance and potential risks that could impact its operations and financial condition.
Trade with 70% Backtested Accuracy
Analyst Views on EVAX
About EVAX
About the author
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunities: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new partners while retaining global rights, although this decision does not impact its cash flow outlook.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, and despite the absence of an approved vaccine, its success could address a significant unmet medical need, enhancing Evaxion's position in vaccine development.
- Financial Stability: Evaxion's cash runway remains unaffected by MSD's decision, extending into the second half of 2027, which ensures continued investment in vaccine development without immediate financial pressure.
- Technological Innovation: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine candidate pipeline and showcasing its technological capabilities and market adaptability under the AI-Immunology™ platform.
Evaxion Unveils EVX-04 Cancer Vaccine, Significantly Inhibiting Tumor Growth
- Vaccine Development Progress: Evaxion's EVX-04 vaccine successfully induces specific T-cell responses and effectively inhibits tumor growth in preclinical models, demonstrating its potential to improve treatment options for acute myeloid leukemia (AML) patients.
- Broad Antigen Coverage: The vaccine identifies and selects 16 non-conventional endogenous retrovirus (ERV) tumor antigen fragments through the AI-Immunology™ platform, ensuring broad coverage across different patients' tumors, thereby enhancing the likelihood of immune recognition.
- Market Demand Alignment: As AML is characterized by high mortality rates and limited existing treatment options, the introduction of EVX-04 not only addresses the urgent need for new therapies but also presents significant commercial opportunities for Evaxion.
- Innovative Technology Application: The
Evaxion Unveils EVX-04 Cancer Vaccine, Prevents Tumor Growth
- Robust Immune Response: Evaxion's EVX-04 cancer vaccine successfully induces specific T-cell responses and significantly prevents tumor growth in preclinical models, indicating its potential value for acute myeloid leukemia (AML) patients.
- Broad Applicability: Developed using the AI-Immunology™ platform, the vaccine targets non-conventional endogenous retrovirus (ERV) tumor antigens, ensuring extensive tumor coverage and applicability across various hard-to-treat cancers, addressing the urgent market need for new therapies.
- Data-Driven Target Selection: By analyzing genomic data from AML patients, EVX-04 selects 16 optimal ERV antigen fragments from five million, ensuring immune recognition and enhancing therapeutic efficacy.
- Immediate Use Vaccine Concept: As an off-the-shelf vaccine, EVX-04 is ready for immediate administration post-diagnosis, aiming to improve treatment options for AML patients and meet the significant unmet medical needs in current treatment modalities.
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours
Biotech Gains in After-Hours Trading: Several biotechnology and pharmaceutical companies saw significant stock price increases in after-hours trading, driven by corporate updates and upcoming events.
Jasper Therapeutics' Webinar Announcement: Jasper Therapeutics, Inc. experienced a 21.51% surge after announcing a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study.
NRx Pharmaceuticals' Presentation at NobleCon21: NRx Pharmaceuticals, Inc. rose 13.39% following the announcement that its CEO will present updates on the company's focus and clinical revenue at an upcoming conference.
Protara Therapeutics' Conference Call: Protara Therapeutics, Inc. gained 5.04% after revealing plans for a conference call to discuss interim data from its Phase 2 trial for bladder cancer, with findings to be presented at a major urology meeting.
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Merck's Decision on EVX-B2: Merck & Co. has opted not to pursue Evaxion's gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek other licensing partners.
Gonorrhea Vaccine Landscape: Despite affecting over 80 million people annually, no gonorrhea vaccine has been approved yet, although preclinical studies show promise for EVX-B2.
Evaxion's Financial Outlook: Evaxion's CEO stated that Merck's decision does not impact their financial projections, which extend to the second half of 2027.
Recent Developments: Evaxion has successfully out-licensed another vaccine candidate, EVX-B3, to Merck, receiving an upfront payment and potential future milestone payments, while the FDA recently approved GSK's oral treatment for gonorrhea.
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunity: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new licensing partners while retaining global rights to the project, although this decision does not impact its cash runway.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, highlighting the potential of Evaxion's AI-Immunology™ platform to develop vaccines that address significant unmet medical needs, despite the absence of approved vaccines to date.
- Financial Stability: Evaxion's cash flow outlook did not include a potential in-licensing of EVX-B2 by MSD, meaning this decision will not affect its cash runway, which is projected to extend into the second half of 2027, ensuring financial flexibility for future R&D activities.
- R&D Direction: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine pipeline and demonstrating the company's ongoing innovation capabilities in addressing infectious diseases.
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
- Change in Partnership Opportunities: MSD's decision not to exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2 allows Evaxion to seek new partners while retaining global rights, although this decision does not impact its cash flow outlook.
- Vaccine Potential: EVX-B2 has demonstrated protective effects against Gonorrhea in preclinical studies, and despite the absence of an approved vaccine, its success could address a significant unmet medical need, enhancing Evaxion's position in vaccine development.
- Financial Stability: Evaxion's cash runway remains unaffected by MSD's decision, extending into the second half of 2027, which ensures continued investment in vaccine development without immediate financial pressure.
- Technological Innovation: Evaxion is also developing an mRNA version of EVX-B2 in collaboration with Afrigen Biologics, further expanding its vaccine candidate pipeline and showcasing its technological capabilities and market adaptability under the AI-Immunology™ platform.
Evaxion Unveils EVX-04 Cancer Vaccine, Significantly Inhibiting Tumor Growth
- Vaccine Development Progress: Evaxion's EVX-04 vaccine successfully induces specific T-cell responses and effectively inhibits tumor growth in preclinical models, demonstrating its potential to improve treatment options for acute myeloid leukemia (AML) patients.
- Broad Antigen Coverage: The vaccine identifies and selects 16 non-conventional endogenous retrovirus (ERV) tumor antigen fragments through the AI-Immunology™ platform, ensuring broad coverage across different patients' tumors, thereby enhancing the likelihood of immune recognition.
- Market Demand Alignment: As AML is characterized by high mortality rates and limited existing treatment options, the introduction of EVX-04 not only addresses the urgent need for new therapies but also presents significant commercial opportunities for Evaxion.
- Innovative Technology Application: The
Evaxion Unveils EVX-04 Cancer Vaccine, Prevents Tumor Growth
- Robust Immune Response: Evaxion's EVX-04 cancer vaccine successfully induces specific T-cell responses and significantly prevents tumor growth in preclinical models, indicating its potential value for acute myeloid leukemia (AML) patients.
- Broad Applicability: Developed using the AI-Immunology™ platform, the vaccine targets non-conventional endogenous retrovirus (ERV) tumor antigens, ensuring extensive tumor coverage and applicability across various hard-to-treat cancers, addressing the urgent market need for new therapies.
- Data-Driven Target Selection: By analyzing genomic data from AML patients, EVX-04 selects 16 optimal ERV antigen fragments from five million, ensuring immune recognition and enhancing therapeutic efficacy.
- Immediate Use Vaccine Concept: As an off-the-shelf vaccine, EVX-04 is ready for immediate administration post-diagnosis, aiming to improve treatment options for AML patients and meet the significant unmet medical needs in current treatment modalities.
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours
Biotech Gains in After-Hours Trading: Several biotechnology and pharmaceutical companies saw significant stock price increases in after-hours trading, driven by corporate updates and upcoming events.
Jasper Therapeutics' Webinar Announcement: Jasper Therapeutics, Inc. experienced a 21.51% surge after announcing a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study.
NRx Pharmaceuticals' Presentation at NobleCon21: NRx Pharmaceuticals, Inc. rose 13.39% following the announcement that its CEO will present updates on the company's focus and clinical revenue at an upcoming conference.
Protara Therapeutics' Conference Call: Protara Therapeutics, Inc. gained 5.04% after revealing plans for a conference call to discuss interim data from its Phase 2 trial for bladder cancer, with findings to be presented at a major urology meeting.
